An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Summary

KX-ORAX-008 is an extension study of patients who completed KX-ORAX-007 without disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and who wish to continue Oraxol treatment.

Timeline

Start

2017-10-25

Primary completion

2019-08-27

Completion

2020-11-12

Outcome

Outcome not reported

Stopped: “No need to complete the overall survival (OS) follow-up as the sample size was too small to interpret OS.”

Drugs

Indications